Brief: BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network And Smilow Cancer Hospital At Yale New Haven
02/07/2025 12:38
July 2 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL HIGHLIGHTS ADDITIONAL PHASE 3 CLINICAL SITES INCLUDING LOS ANGELES CANCER NETWORK AND SMILOW CANCER HOSPITAL AT YALE NEW HAVEN BRIACELL THERAPEUTICS CORP: ANTICIPATES COMPLETING PATIENT ENROLLMENT IN LATE 2025 OR EARLY 2026 AND MAY REPORT TOP LINE DATA AS EARLY AS H1-2026 Source text: ID:nGNX16pf46 Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study